Alzheimer's disease pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
==Pathogenesis== | ==Pathogenesis== | ||
Alzheimer disease (AD), is a progressive neurodegenerative disorder. The dysfunction of amyloid precursor protien (APP) metabolism and the resulting build up of of Aβ peptides and their aggregation in the form of senile plaques in the brain parenchyma of individuals have been considered pivotal for neurodegeneration in the disease. There is also an accumulation of intracellular neurofibrillary tangles that consist of hyperphosphorylated tau protein and a profound loss of basal forebrain cholinergic neurons that innervate the hippocampus, and the neocortex. | Alzheimer disease (AD), is a progressive neurodegenerative disorder. The dysfunction of amyloid precursor protien (APP) metabolism and the resulting build up of of Aβ peptides and their aggregation in the form of senile plaques in the brain parenchyma of individuals have been considered pivotal for neurodegeneration in the disease. There is also an accumulation of intracellular neurofibrillary tangles that consist of hyperphosphorylated tau protein and a profound loss of basal forebrain cholinergic neurons that innervate the hippocampus, and the neocortex. | ||
* The pathogenesis of Alzheimer's dementia (AD) can be explained by three pathological processes. The processes inloved in the development of AD and their molecular basis is as follows: | * The pathogenesis of Alzheimer's dementia (AD) can be explained by three pathological processes. The processes inloved in the development of AD and their molecular basis is as follows:<ref name="pmid20413653">{{cite journal |vauthors=Crews L, Masliah E |title=Molecular mechanisms of neurodegeneration in Alzheimer's disease |journal=Hum. Mol. Genet. |volume=19 |issue=R1 |pages=R12–20 |year=2010 |pmid=20413653 |pmc=2875049 |doi=10.1093/hmg/ddq160 |url=}}</ref> | ||
=== (i) Neuronal loss === | === (i) Neuronal loss === | ||
* Initial synaptic injury is followed by neuronal loss accompanied by astrogliosis and microglial cell proliferation. | * Initial synaptic injury is followed by neuronal loss accompanied by astrogliosis and microglial cell proliferation.<ref name="pmid2531723">{{cite journal |vauthors=Beach TG, Walker R, McGeer EG |title=Patterns of gliosis in Alzheimer's disease and aging cerebrum |journal=Glia |volume=2 |issue=6 |pages=420–36 |year=1989 |pmid=2531723 |doi=10.1002/glia.440020605 |url=}}</ref><ref name="pmid2531723">{{cite journal |vauthors=Beach TG, Walker R, McGeer EG |title=Patterns of gliosis in Alzheimer's disease and aging cerebrum |journal=Glia |volume=2 |issue=6 |pages=420–36 |year=1989 |pmid=2531723 |doi=10.1002/glia.440020605 |url=}}</ref> | ||
* Cognitive impairment in patients with AD is closely associated with synaptic loss in the neocortex and limbic system | * Cognitive impairment in patients with AD is closely associated with synaptic loss in the neocortex and limbic system<ref name="pmid2360787">{{cite journal |vauthors=DeKosky ST, Scheff SW |title=Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity |journal=Ann. Neurol. |volume=27 |issue=5 |pages=457–64 |year=1990 |pmid=2360787 |doi=10.1002/ana.410270502 |url=}}</ref><ref name="pmid1789684">{{cite journal |vauthors=Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R |title=Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment |journal=Ann. Neurol. |volume=30 |issue=4 |pages=572–80 |year=1991 |pmid=1789684 |doi=10.1002/ana.410300410 |url=}}</ref> | ||
=== (ii) Aggregation of amyloid β (Aβ) === | === (ii) Aggregation of amyloid β (Aβ) === | ||
Revision as of 18:12, 17 September 2017
| https://https://www.youtube.com/watch?v=v5gdH_Hydes%7C350}} |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Alzheimer's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Alzheimer's disease pathophysiology On the Web |
|
American Roentgen Ray Society Images of Alzheimer's disease pathophysiology |
|
Risk calculators and risk factors for Alzheimer's disease pathophysiology |
Overview
Pathogenesis
Alzheimer disease (AD), is a progressive neurodegenerative disorder. The dysfunction of amyloid precursor protien (APP) metabolism and the resulting build up of of Aβ peptides and their aggregation in the form of senile plaques in the brain parenchyma of individuals have been considered pivotal for neurodegeneration in the disease. There is also an accumulation of intracellular neurofibrillary tangles that consist of hyperphosphorylated tau protein and a profound loss of basal forebrain cholinergic neurons that innervate the hippocampus, and the neocortex.
- The pathogenesis of Alzheimer's dementia (AD) can be explained by three pathological processes. The processes inloved in the development of AD and their molecular basis is as follows:[1]
(i) Neuronal loss
- Initial synaptic injury is followed by neuronal loss accompanied by astrogliosis and microglial cell proliferation.[2][2]
- Cognitive impairment in patients with AD is closely associated with synaptic loss in the neocortex and limbic system[3][4]
(ii) Aggregation of amyloid β (Aβ)
- Amyloid precurosr protein (APP) is physiologically present in normal brains
- It is proteolytically processed by α-, β-, and γ-secretases following two pathways:
Constitutive (nonamyloidogenic) pathway
- In the constitutive pathway, proteolysis of APP by α- and γ-secretases results in nonpathogenic fragments (sAPPα and α-C-terminal fragment)
Amyloidogenic pathway
- In the amyloidogenic pathway, proteolysis of APP by β-secretase and γ-secretase gives rise to a mixture of Aβ peptides with different lengths. There are two major Aβ species: Aβ1–40 (90%) and Aβ1–42 (10%). The Aβ1–42 fragments are more aggregation-prone and are predominantly present in amyloid plaques in brains of AD patients.
(iii) Formation of intraneuronal neurofibrillary tangles
Triggers
The following factors lead to the development of Alzheimer's dementia:
- Genetic factors
- Environmental factors
- Chromosomal factors
Genetic Factors
Genetic origin of Alzheimer's dementia (AD) demonstrates an autosomal dominant pattern of inheritance. Alzheimer's dementia arising from genetic alterations may lead to early onset (<60 years) of disease. The following mutations are implicated in the development of AD are:
Early onset (Alzheimer's dementia-AD 1, 3 and 4)
30-50 percent of early-onset Alzheimer's dementia (AD) is associated with an autosomal dominant inheritance and consists of mutations in the following genes:
- Presenilin1 (PS1) gene, also called PSEN1 gene on chromosome 14 (AD3- 20 to 30 percent cases)
- Presenilin 2 (PS2) gene, also called PSEN2 gene on chromosome 1 (AD4- rare)
- Point mutations in amyloid beta A4 protein gene, also called amyloid precursor protein (APP) gene on chromosome 21 are associated in some cases of early onset (< 65 yr) familial AD cases
Late onset (Alzheimer's dementia -AD2)
- Apolipoprotein 4 gene (APOE4) mutation is associated with late onset (>60 years) Alzheimer's dementia (AD)
- p.Arg47His allelic variant in TREM2 gene
Hypotheses for Alzheimer's dementia
Two major hypothses for the development of Alzheimer's dementia (AD) have been proposed:
Amyloid cascade hypothesis
Associated Conditions
References
- ↑ Crews L, Masliah E (2010). "Molecular mechanisms of neurodegeneration in Alzheimer's disease". Hum. Mol. Genet. 19 (R1): R12–20. doi:10.1093/hmg/ddq160. PMC 2875049. PMID 20413653.
- ↑ 2.0 2.1 Beach TG, Walker R, McGeer EG (1989). "Patterns of gliosis in Alzheimer's disease and aging cerebrum". Glia. 2 (6): 420–36. doi:10.1002/glia.440020605. PMID 2531723.
- ↑ DeKosky ST, Scheff SW (1990). "Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity". Ann. Neurol. 27 (5): 457–64. doi:10.1002/ana.410270502. PMID 2360787.
- ↑ Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991). "Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment". Ann. Neurol. 30 (4): 572–80. doi:10.1002/ana.410300410. PMID 1789684.